PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with ...
New biomarker may facilitate monitoring T1D patients’ health Increase in PD-1+ T-cells correlated with therapeutic response and less insulin use Gdańsk, Poland – 4 April 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology …